In today’s briefing:
- Corteva, Inc.: Initiation of Coverage – Business Strategy, Pro Farm Agreement, Herbicides Update, Financial Forecasts, DCF & Comparables Valuation, Key Risks (07/22)
- BioMarin Pharmaceutical: Initiation of Coverage – Business Strategy, Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (07/22)
Corteva, Inc.: Initiation of Coverage – Business Strategy, Pro Farm Agreement, Herbicides Update, Financial Forecasts, DCF & Comparables Valuation, Key Risks (07/22)
- This is our first report on Corteva, a major agricultural player within the seeds and crop protection domain.
- The company registered its Enlist Duo and Enlist One herbicides through 2029 with the U.S.
- EPA.
BioMarin Pharmaceutical: Initiation of Coverage – Business Strategy, Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (07/22)
- This is our first report on rare disease specialist, BioMarin Pharma.
- The company had a decent start to 2022 recording $519 million in total revenues in the previous quarter.
- The $20 million in Voxzogo contributions during the first quarter increased the company’s full-year 2022 guidance to between $100 million and $125 million and will play a significant role in its future growth.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
